Abstract
Objective
To determine the value of CT and dynamic contrast-enhanced (DCE-)MRI for monitoring denosumab therapy of giant cell tumors of bone (GCTB) by correlating it to histopathology.
Materials and methods
Patients with GCTB under denosumab treatment and monitored with CT and (DCE-)MRI (2012-2021) were retrospectively included. Imaging and (semi-)quantitative measurements were used to assess response/relapse. Tissue samples were analyzed using computerized segmentation for vascularization and number of neoplastic and giant cells. Pearson’s correlation/Spearman’s rank coefficient and Kruskal-Wallis tests were used to assess correlations between histopathology and radiology.
Results
Six patients (28 ± 8years; five men) were evaluated. On CT, good responders showed progressive re-ossification (+7.8HU/month) and cortical remodeling (woven bone). MRI showed an SI decrease relative to muscle on T1-weighted (−0.01 A.U./month) and on fat-saturated T2-weighted sequences (−0.03 A.U./month). Time-intensity-curves evolved from a type IV with high first pass, high amplitude, and steep wash-out to a slow type II. An increase in time-to-peak (+100%) and a decrease in Ktrans (−71%) were observed. This is consistent with microscopic examination, showing a decrease of giant cells (−76%), neoplastic cells (-63%), and blood vessels (−28%). There was a strong statistical significant inverse correlation between time-to-peak and microvessel density (ρ = −0.9, p = 0.01). Significantly less neoplastic (p = 0.03) and giant cells (p = 0.04) were found with a time-intensity curve type II, compared to a type IV. Two patients showed relapse after initial good response when stopping denosumab. Inverse imaging and pathological findings were observed.
Conclusion
CT and (DCE-)MRI show a good correlation with pathology and allow adequate evaluation of response to denosumab and detection of therapy failure.
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
Introduction
Giant cell tumor of bone (GCTB) is characterized by neoplastic proliferating mononuclear stromal cells (NC) and osteoclast-like giant cells (GC). The NCs express receptor activator of nuclear factor kappa-B-ligand (RANKL), which binds to RANK on the GCs and endothelial cells, inducing cell activation and neovascularization, leading to bone resorption. A total of 96% of GCTB have a driver mutation of glycine 34 in H3F3A in the NC which is useful for the (differential) diagnosis. Despite the benign character, GCTB can be locally aggressive and can metastasize in 5.1% [1,2,3,4].
GCTB predominantly occurs between 20 and 45 years, without clear sex preference. It accounts for 20% of benign bone tumors [2, 3]. A total of 70% of GCTB are located in the epiphysis of long bones and 25% in flat bones [2, 3]. The epiphyseal location leads to joint dysfunction and sometimes pathological fractures. Mechanical and activity-dependent pain are the most prominent symptoms [3, 5].
The treatment of choice is curettage with or without local adjuvant or resection. Local recurrence is seen in 15-50%, with a higher risk after curettage without local adjuvants [1, 2]. Denosumab was introduced to treat skeletally mature patients with inoperable GCTB [5, 6]. It is a fully humanized monoclonal antibody targeting RANKL, inhibiting GC and endothelial activation and inducing apoptosis. Histologically, response to denosumab is defined as >90% decrease of GCs [5, 7]. Clinical and histological improvement is observed by symptom decrease, woven bone formation, and calcification with rim formation. Due to the interaction between GCs and NCs, a reduction of NCs is also observed. However, they continue to proliferate at a slower pace [1, 5, 6, 8].
Because of the high recurrence risk, a good follow-up schedule when interrupting treatment is necessary [9,10,11]. While imaging plays a crucial role in the diagnosis and follow-up of GCTB, objective studies on lesion evolution and pathological correlation are missing. Conventional radiographs display all features for GCTB diagnosis. In follow-up and operative planning, CT assesses cortical thinning, pathologic fractures, and fracture consolidation, while MRI evaluates soft tissue invasion. Dynamic contrast-enhanced (DCE-)MRI evaluates tumoral microcirculation in a non-invasive way (vessel density, vascular permeability, perfusion, extravascular space, and interstitial volume) [12]. Figure 1 illustrates the functioning of GCTB and the effect of denosumab on bone and blood vessels [13,14,15,16].
This proof-of-concept study on six patients aims to describe the effects of denosumab on imaging and pathological findings and evaluates the value of CT and (DCE-)MRI for follow-up during treatment in good and poor responders, with pathological correlation.
Methods
Patient population
Institutional review board approval (BC-11285) and informed consent were obtained. Patients with GCTB under denosumab treatment (2012-2021, Ghent University Hospital) were retrospectively included. Exclusion criteria for initially eligible patients were absence of histopathology and (DCE-)MRI examination more than 6 months before biopsy/curettage (Figure 2). Diagnosis was histologically confirmed by a pathologist with 15 years of experience in bone tumors (D.C.). Finally, six patients were included. All patients had a biopsy before denosumab treatment and four patients also had a curettage after denosumab treatment, providing histopathological slides for correlation with radiology. All patients received follow-up with CT and (DCE-)MRI, alternating, six-monthly. One CT and one (DCE-)MRI (closest to biopsy/curettage) were analyzed before and after denosumab treatment for all patients. Imaging and pathology samples were in average 2 (±2) months away from each other. Two patients had a late curettage after denosumab treatment and showed recurrence; in these patients, a third (DCE-)MRI was also analyzed after denosumab treatment, before recurrence occurred.
CT imaging
CT was performed using Somatom Definition Flash (Siemens, Erlangen, Germany). Slice thickness varied from 1 to 3 mm. Largest diameter in three orthogonal directions was measured. In addition, the mean Hounsfield unit (HU) and the surface area of the giant cell tumor of bone were calculated on all slices. Volume (Eq. 1) and surface-weighted average HU (Eq. 2) were calculated to follow up over time. The changes were correlated with changes on the histopathological samples.
MR imaging
1.5T MRI studies were obtained on Magnetom Avanto Fit and Symphony Tim devices (Siemens, Erlangen, Germany). Slice thickness and spacing varied from 2.0 to 6.0 mm and 2.2 to 7.2 mm, respectively. DCE-MRI was performed with a T1-weighted (T1w) 3D Twist-Vibe sequence. Largest diameter in three orthogonal directions was measured on T1w sequences. In addition, mean signal intensity (SI) and surface area were calculated on T1w-saturated and fat-saturated T2w (T2FSw) sequences on all slices to calculate the surface-weighted SI on T1w and T2FSw sequences, to follow up over time (Eq. 3). As a reference, the SI of a fat-free muscle region-of-interest was measured. The same muscle was used between MRI studies in time. Finally, the mean tumoral SI relative to muscle was calculated (Eq. 4).
Both on CT and MRI imaging, all imaging measurements and tumoral segmentations were performed by two pretrained observers (M.L. and T.V.D.B. with 3 and 4 years of experience in bone tumor imaging, respectively) under direct supervision of K.V. (musculoskeletal radiologist with more than 35 years of experience) to increase accuracy. All available CT and MRI sequences were used and correlated in order to perform pixel-by-pixel detailed manual segmentation of the tumoral borders and to perform detailed measurements. Inter-reader analysis was not performed since all cases of GCTB could be clearly delineated leading to highly consistent measurements by multiple observers, both at diagnosis and during treatment follow-up. For different follow-up CT and MRI studies, the exact same segmentation areas were maintained.
The DCE-MRI was evaluated using SyngoVia VB50 (Siemens, Erlangen, Germany). The region-of-interest captured the entire tumor on the slice with the largest diameter. A second and third region-of-interest was drawn in a reference fat-free region of a muscle and a blood vessel (zone without flow artifacts) to calculate relative parameters and was kept constant between follow-up DCE-MRI studies. First, a qualitative analysis was performed by evaluating the time-intensity curves (TIC), reflecting the exchange of gadolinium contrast agent between the intravascular and interstitial space with characteristic curve types (Figure 3A) [17,18,19]. Secondly, semi-quantitative analysis was performed by describing the characteristics of the TIC: The wash-in slope, wash-out slope, time-to-peak (TTP), positive enhancement integral, and area-under-the-curve were calculated. Moreover, the Ktrans (volume transfer constant), Ve (extracellular-extravascular-volume-fraction), and Kep (efflux rate constant) were calculated (modified Tofts model). The area-under-the-curve was calculated from the time-concentration curve [18, 20].
Pathology
The tissue samples were subjected to 4% formalin fixation and paraffin embedding. Bone-rich tissue was decalcified by the use of standard procedures with incubation in EDTA. Subsequently, 4-μm tissue sections were cut and stained with H&E. Immunohistochemistry was performed on 4-μm-thick sections of formalin-fixed, paraffin-embedded material with a Benchmark XT immunostainer (Ventana Medical Systems, Tucson, AZ, USA). Primary monoclonal antibodies were CD34 (1:100; QBEnd10; Dako, Denmark) and H3.3 G34W (1:800; RM263; RevMAb Biosciences, USA). Visualization was achieved with the Ultraview Universal DAB Detection kit (Ventana Medical Systems, Tucson, AZ, USA). Appropriate positive and negative controls were used throughout.
The slide with largest diameter was double-stained with CD34 (function: vascularization; color: red) and Histone 3.3 (H3F3A) G34W (H3.3G34W) (function: NCs; color: brown) and scanned using the Nanozoomer 2.0-RS (Hamamatsu Photonics, Shizuoka, Japan) (Figure 3B). Computerized segmentation was performed using HALO 2022 (Indica Labs, Albuquerque, New Mexico, USA) using artificial intelligence. Several Dense Convolutional Networks (DenseNet) were trained with annotations reviewed by a pathologist (D.C.) [21]. The final AI analysis was evaluated on a slide-by-slide level by the pathologist and corresponded with his evaluation.
The first DenseNet differentiated between necrosis and viable tissue. Necrotic areas with negative staining were excluded. The second DenseNet segmented blood vessels and pools (Figure 3C). A blood pool is a cavity with red blood cells and <50% surrounding endothelial cells, whereas a blood vessel has ≥50% endothelial cells. The blood vessel area (mm2) and the number of blood vessels were counted and divided by the viable tissue area parameters to calculate the blood vessel area fraction (BVarea, %, Eq. 5) and the microvessel density (MVD) (Eq. 6).
Furthermore, a third and a fourth DenseNet were trained for calculating the number of GCs and NCs (Figure 3 D/E). Those were divided by the viable tissue area as well (Eqs. 7 and 8).
A semi-quantitative evaluation was made by a pathologist (D.C.) to evaluate the blood-pool-area-fraction of all slides from one tumor and the woven bone area fraction in the treated tumor (new bone formed by osteoblasts). An example of a typical area of woven bone is illustrated in Figure 3F.
Statistical analysis
CT and/or (DCE-)MRI were available shortly before or after curettage or biopsy to assess correlation between pathology and (DCE-)MRI parameters. Statistical analysis was performed with SPSS Statistics 28 (IBM, Armonk, New York, USA). Non-parametric tests were used because of the small sample size. The Pearson’s correlation and Spearman’s rank coefficient were calculated. In addition, the Kruskal-Wallis test by ranks was calculated to compare the distribution of pathology parameters across groups with a different TIC type. The significance level was set at p < 0.05 for all statistical tests.
Because all patients that were not treated with denosumab underwent initial tumoral resection, no control group was included.
Results
Patient characteristics
Because one sample was negative for H3.3G34W staining, which is highly sensitive (91-93%) and specific (99%) for the diagnosis of GCTB [22, 23], the decision was made to exclude this case from further statistical analysis (Figure 2).
A total of six patients (mean 28 ± 8 years; five males) were included in this proof-of-concept study. Patient characteristics are displayed in Table 1. Two patients underwent curettage, 9 and 10 months after stopping denosumab because of recurrence (Table 1, patients 3 and 4) and two patients had a curettage 4 and 5 months after stopping denosumab (Table 1, patients 1 and 2), without recurrence of GCTB. One patient had a dental problem after a tooth extraction with a difficult and prolonged wound recovery, and one patient discontinued denosumab therapy because of a pregnancy wish. Both situations are known to be at risk of complications. Two patients did not stop denosumab treatment, so they did not have a curettage after denosumab treatment (Table 1, patients 5 and 6). The mean follow-up time was 6 ± 3 years (range 2-9).
Correlation of DCE-MRI with histopathology
No correlations were found using the tumoral DCE-MRI parameters relative to arterial enhancement. The parameters relative to muscle were more representative so only those were described.
Statistically significant linear correlations were found between MVD and TTP (r = −0.8; p = 0.02), between MVD and Ktrans (r = 0.8; p = 0.04), between blood-pool-area-fraction and Ktrans (r = -0.9; p = 0.01) and between blood-pool-area-fraction and area-under-the-time-concentration curve (r = −0.8; p = 0.04). Moreover, more statistically significant correlations were found with the Spearman’s test. Strongest correlations were the correlation of MVD with TTP (ρ = −0.9; p = 0.01), MVD with the efflux rate constant (Kep) (ρ = 0.9; p = 0.01), MVD with positive enhancement integral (ρ = 0.9; p = 0.01), and blood-pool-area-fraction with area-under-the-time-concentration curve (ρ = −0.9; p = 0.01). Overall, the blood vessel area fraction and MVD showed correlations with the same DCE-MRI parameters, but MVD had more and stronger statistically significant correlation coefficients (Table 2).
Cases with a type IV TIC contained most NCs, GCs, and blood vessels. Cases with type V TIC had less NC, GC, and blood vessels, and cases with type II TIC had the least NCs, GCs, and blood vessels. Table 3 shows the mean, the standard deviation, and the range of NCs, GCs, and MVD of GCTBs with TIC curve types II, IV, and V. Moreover, a GCTB with TIC type II had statistically significant less NCs (p = 0.03) and GCs (p = 0.04) than a GCTB with TIC type IV (Figure 4).
Effects of denosumab on imaging and pathology with correlation
On CT, a tumor volume decrease was observed (mean −0.05 cm3/month); however, the volume before and after denosumab treatment was not significantly different. An HU increase (re-ossification, mean +7.8 HU/month) was observed after denosumab treatment, which correlates microscopically with woven bone from the two patients undergoing curettage 4-5 months after stopping denosumab. On average, the woven bone area fraction of the microscopic slides was 80%. However, a re-occurrence of an HU decrease (new osteolysis) in the two patients undergoing curettage 9-10 months after therapy stop was observed. Microscopically, this was associated with only a few woven bone spots (5% of the slides) (Figure 5).
On MRI, all patients under denosumab treatment showed an SI decrease relative to muscle on T1w and T2FSw sequences with an average of −0.01 and −0.03 A.U./month, respectively. This correlates with woven bone formation on pathology. When denosumab was discontinued, the SI relative to muscle of T1w and T2FSw sequences increased again, even faster than the decrease under treatment (+0.05 and +0.09 A.U./month, respectively). This is indicative of disappearance of woven bone and increasing tumoral infiltration. Only a few spots of woven bone on pathology in those two patients were identified (5% of the slide).
When analyzing the DCE-MRI, initially all patients receiving treatment with denosumab had a TIC shift from type IV to II (and to type V in one patient), an area-under-the-time-intensity-curve (mean −72%) and Ktrans (mean −71%) decrease and TTP (mean +100%) increase. The second phase of TIC changed as well from a negative to a positive wash-out slope indicating continuous wash-in instead of a rapid wash-in and wash-out phenomenon, which is characteristic for a decrease in blood vessels and a larger extracellular volume to distribute the gadolinium contrast agent inflow. All parameters but wash-out slope and the extracellular-extravascular-volume-fraction showed significant changes (Table 4). These findings corresponded with pathology, where patients treated with denosumab had a decrease in MVD (mean −28%), in GC/mm2 (mean −76%), and in NC/mm2 (mean −63%). All patients treated with denosumab also showed an increase in blood pools (mean +84%).
When stopping denosumab, TIC shifted to a type IV curve again indicating a relapse. Table 5 and Figure 6 show the differences in (DCE-)MRI parameters and in pathology parameters of the two patients who had a curettage early after stopping denosumab (4–5 months), compared to the two patients who had a late curettage after stopping denosumab (9–10 months). Patients with early curettage showed a decrease in T1w and in T2FSw SI, compared to an increase in SI in patients with a late curettage. Patients with a late curettage show a lower decrease in wash-in slope, area-under-the-time-intensity-curve, Ktrans, area-under-the-time-concentration-curve, MVD, GCs, and NCs and a lower increase in TTP and blood-pool-area-fraction after denosumab treatment compared to patients with early curettage, indicating recurrence.
Correlation of vascularization and aggressiveness
A statistically significant association was observed between MVD and cortical breakthrough. All patients with an MVD higher than 130 vessels/mm2 (three patients) had cortical breakthrough as observed on CT/MRI imaging. No correlation was found with the blood vessel area fraction or tumor size.
Discussion
A strong linear correlation was found between MVD and Ktrans, while a strong linear inverse correlation was found between MVD and TTP. A higher density of blood vessels allows faster inflow of gadolinium contrast agent into the GCTB, increasing the Ktrans and shortening the TTP. Between MVD and wash-in slope, only a significant rank correlation coefficient was found, which suggests that wash-in slope is, apart from the MVD, more influenced by other parameters that were not assessed (e.g., capillary permeability). No correlation was found with the extracellular-extravascular-volume-fraction (Ve), probably because it is strongly influenced by the viscosity/bulk water flow of the extracellular space, which was not assessed. Additionally, a linear inverse correlation was found between the blood-pool-area-fraction and the Ktrans. Ktrans reflects the combined effects of plasma blood flow and blood vessel permeability. Blood pools are large cavities, which are not delineated by endothelial cells, filled with red blood cells. In such large cavities, the bulk water flow approaches zero, explaining why the Ktrans decreases with increased blood pools. The area-under-the-time-concentration-curve was inversely correlated with blood-pool-area-fraction, which is also regulated by the blood flow. The GCs and the NCs correlated with the TIC type: A TIC type IV had significantly more GCs and NCs compared to a type II.
The effect of denosumab treatment was pathologically more pronounced on the GCs than on the NCs. This can be explained by denosumab having a direct effect on the GCs by preventing the RANKL to bind to the RANK. Some NCs will always survive between the newly formed woven bone trabeculae. This can be the reason why patients relapsed after discontinuing denosumab treatment, as described in previous studies and in our study population [1, 5, 6, 8]. Following our data, recurrence is most likely to occur around 9-10 months after discontinuing treatment. Even after curettage, NCs tend to survive in the margins of the tumor, with a high risk of recurrence.
Susarla et al. stated that GCTB of the jaw, with a blood vessel area fraction of >2.5%, was significantly more aggressive. In their classification system, they analyzed the largest tumoral diameter and cortical breakthrough. In this study, no significant association with the blood vessel area fraction was observed. However, there was a significant correlation between MVD and cortical breakthrough [13]. This supports their conclusion that vascularization of GCTB is associated with aggressiveness. Min et al. stated that vascular endothelial growth factor induces RANK expression by endothelial cells, making them more responsive to RANKL effects. Moreover, RANKL stimulates the survival of endothelial cells, promotes neo-angiogenesis, and increases vascular permeability, independently from vascular endothelial growth factor activity. This theory could explain the association between high vascularization and aggressiveness [14,15,16]. This would also explain why MVD decreases under denosumab treatment. As denosumab binds to RANKL, less RANKL would be available to stimulate the survival of endothelial cells. Additionally, the vascular permeability would decrease under denosumab.
This article is a proof-of-concept study on the correlation between imaging assessment and histology on six patients. All patients were used for evaluation of correlation between pathology and DCE-MRI. Other groups have studied the effects of denosumab on pathology in larger patient groups. However, we study the effect of denosumab on vascularization, tumoral cells, tumoral microenvironment, bone formation, and imaging findings by correlating them to pathology. This proof-of-concept study shows a good correlation between pathology and radiology, especially between the MVD and TTP and between the curve type and the numbers of NCs and GCs. However, because of the small sample size, extrapolation of results to all patients should be done with some caution. Larger multicenter studies with a larger study population are needed in the future to confirm or fine-tune these findings.
A limitation of this small study is that pathology only samples a small part of a larger tumor. Because this is a retrospective study, no point-to-point correlation could be performed. Future studies should add a point-to-point correlation between different zones on both CT/MRI evaluation and histopathology to assess the true nature of different tumoral components. In conclusion, pathological response to denosumab shows a decrease of approximately 97% of GCs, accompanied by a decreased MVD of 32%. On DCE-MRI, this correlates with an increase of TTP by approximately 100% and a change of TIC from type IV to type II. As soon as denosumab is stopped, GCs start proliferating again and NCs are stimulated. This is accompanied with an increase in MVD, a decrease of approximately 37% in TTP, and the time TIC type changing again to type IV. On CT, a tumor volume decrease (mean −0.05 cm3/month) and an HU increase (re-ossification, mean +7.78 HU/month) were observed. These results suggest that CT and DCE-MRI can help to guide diagnostic and follow-up decisions of GCTB. Larger international studies are needed to validate these results.
Data availability
Data generated or analyzed during the study are available upon reasonable request.
References
Chawla S, Blay J-Y, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, et al. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019;20(12):1719–29.
WHO Classification of Tumours Editorial Board. Soft Tissue and Bone Tumours: WHO Classification of Tumours (Medicine). 5th ed. International Agency for Research on Cancer; 2020.
Santini E, Kalil RK, Franco Bertoni Y-KP. Tumors and tumorlike lesions of bone, vol. 25. Springer; 1994. p. 593–3.
Presneau N, Baumhoer D, Behjati S, Pillay N, Tarpey P, Campbell PJ, et al. Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics. J Pathol Clin Res [Internet]. 2015;1(2):113–23. https://doi.org/10.1002/cjp2.13.
Zhang R, Ma T, Qi D, Zhao M, Hu T, Zhang G. Short-term preoperative denosumab with surgery in unresectable or recurrent giant cell tumor of bone. Orthop Surg. 2019;11(6):1101–8.
Lipplaa A, Dijkstra S, Gelderblom H. Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone. Curr Opin Oncol. 2019;31(4):329–35.
van der Heijden L, Dijkstra PDS, Blay J-Y, Gelderblom H. Giant cell tumour of bone in the denosumab era. Eur J Cancer. 2017;77:75–83.
Mak IWY, Evaniew N, Popovic S, Tozer R, Ghert M. A translational study of the neoplastic cells of giant cell tumor of bone following neoadjuvant denosumab. J Bone Joint Surg Am. 2014;96(15):e127.
Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay J-Y, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010;11(3):275–80.
Chawla S, Henshaw R, Seeger L, Choy E, Blay J-Y, Ferrari S, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013;14(9):901–8.
Gossai N, Hilgers MV, Polgreen LE, Greengard EG. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone. Pediatr Blood Cancer. 2015;62(6):1078–80.
van Langevelde K, McCarthy CL. Radiological findings of denosumab treatment for giant cell tumours of bone. Skeletal Radiol. 2020;49(9):1345–58.
Susarla SM, August M, Dewsnup N, Faquin WC, Kaban LB, Dodson TB. CD34 staining density predicts giant cell tumor clinical behavior. J Oral Maxillofac Surg. 2009;67(5):951–6.
Girolami I, Mancini I, Simoni A, Baldi GG, Simi L, Campanacci D, et al. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series. J Clin Pathol. 2016;69(3):240–7.
Yang Y-Q, Tan Y-Y, Wong R, Wenden A, Zhang L-K, Rabie ABM. The role of vascular endothelial growth factor in ossification. Int J Oral Sci. 2012;4(2):64–8.
Min J-K, Cho Y-L, Choi J-H, Kim Y, Kim JH, Yu YS, et al. Receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) increases vascular permeability: impaired permeability and angiogenesis in eNOS-deficient mice. Blood. 2007;109(4):1495–502.
van der Woude HJ, Verstraete KL, Hogendoorn PC, Taminiau AH, Hermans J, Bloem JL. Musculoskeletal tumors: does fast dynamic contrast-enhanced subtraction MR imaging contribute to the characterization? Radiology. 1998;208(3):821–8.
Lavini C, de Jonge MC, van de Sande MGH, Tak PP, Nederveen AJ, Maas M. Pixel-by-pixel analysis of DCE MRI curve patterns and an illustration of its application to the imaging of the musculoskeletal system. Magn Reson Imaging. 2007;25(5):604–12.
Van Den Berghe T, Verstraete KL, Lecouvet FE, Lejoly M, Dutoit J. Review of diffusion-weighted imaging and dynamic contrast-enhanced MRI for multiple myeloma and its precursors (monoclonal gammopathy of undetermined significance and smouldering myeloma). Skeletal Radiol. 2022;51(1):101–22.
Cuenod CA, Balvay D. Perfusion and vascular permeability: basic concepts and measurement in DCE-CT and DCE-MRI. Diagn Interv Imaging [Internet]. 2013;94(12):1187–204. https://doi.org/10.1016/j.diii.2013.10.010.
Huang G, Liu Z, Van Der Maaten L, Weinberger KQ. Densely connected convolutional networks. In: 2017 IEEE Conference on Computer Vision and Pattern Recognition (CVPR); 2017. p. 2261–9.
Amary F, Berisha F, Ye H, Gupta M, Gutteridge A, Baumhoer D, et al. H3F3A (Histone 3.3) G34W immunohistochemistry: a reliable marker defining benign and malignant giant cell tumor of bone. Am J Surg Pathol. 2017;41(8):1059–68.
Yang L, Zhang H, Zhang X, Tang Y, Wu Z, Wang Y, et al. Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): analysis of 21 cases. Ann Diagn Pathol [Internet]. 2022;57:151882. https://www.sciencedirect.com/science/article/pii/S1092913421001829
Acknowledgements
We would like to thank for technical support Sukru Karanfil, Ran Rumes and Lynn Supply from the pathology department. We would also like to thank Louis Deconinck for his help with the data analysis.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Lejoly, M., Van Den Berghe, T., Creytens, D. et al. Diagnosis and monitoring denosumab therapy of giant cell tumors of bone: radiologic-pathologic correlation. Skeletal Radiol 53, 353–364 (2024). https://doi.org/10.1007/s00256-023-04403-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00256-023-04403-7